Use of nerve growth factor to treat congenital neurotrophic corneal ulceration
- PMID: 16633039
- DOI: 10.1097/01.ico.0000176609.42838.df
Use of nerve growth factor to treat congenital neurotrophic corneal ulceration
Abstract
Purpose: This study was designed to assess the efficacy of nerve growth factor in the treatment of neurotrophic corneal ulceration in a child with bilateral congenital corneal anesthesia secondary to trigeminal insufficiency.
Methods: A 5-month-old child presented to the casualty department with a 2-week history of red eyes and right corneal ulceration. Slit-lamp examination showed a central defect in the right corneal epithelium with underlying stromal opacification, only mild conjunctival inflammation with slight decreased tear production, and otherwise apparently normal eyes. Initially this was investigated as an infected ulcer and treated for several weeks as herpetic ulceration with no beneficial effect. Further clinical examination demonstrated bilateral decreased corneal sensation along with decreased facial sensation in keeping with congenital trigeminal nerve insufficiency. Investigation with magnetic resonance imaging showed no obvious abnormality. Conservative treatment with lubricants resulted in progressive right corneal stromal loss, and no healing occurred in the left corneal ulcer. Bilateral large lateral tarsorrhaphies were performed. Despite this, the left corneal ulcer demonstrated no improvement and increasing stromal opacification was noted. Topical nerve growth factor (NGF) was then used to treat the left cornea and resulted in epithelial healing within 1 week. Treatment was continued for a further 10 days after epithelial healing. Despite conventional treatment on 3 separate occasions, further epithelial breakdown occurred. Topical NGF treatment resulted in a rapid improvement and healing of the epithelial defect.'At present, the patient is receiving a 6-month continuous treatment plan of NGF.
Results: Persistent epithelial defects (PED) secondary to neurotrophic ulceration have responded to topical NGF on 3 separate occasions during a 2-year period. The corneal epithelium now remains intact, and the cornea has no vascularization; however, mild anterior stromal opacification has gradually increased despite prolonged NGF treatment.
Conclusion: NGF seems to represent a safe and efficacious treatment option to restore the integrity of corneal epithelium in which there is congenital corneal anesthesia because of trigeminal insufficiency. However, this treatment alone is insufficient to prevent progressive anterior stromal opacification.
Similar articles
-
Topical treatment with nerve growth factor for neurotrophic keratitis.Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2. doi: 10.1016/s0161-6420(00)00163-9. Ophthalmology. 2000. PMID: 10889110 Clinical Trial.
-
Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis.Ophthalmology. 2007 Sep;114(9):1637-42. doi: 10.1016/j.ophtha.2006.12.014. Epub 2007 Mar 26. Ophthalmology. 2007. PMID: 17382396
-
Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers.Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8181-5. doi: 10.1167/iovs.12-10476. Invest Ophthalmol Vis Sci. 2012. PMID: 23150626 Clinical Trial.
-
Clinical application of nerve growth factor on human corneal ulcer.Arch Ital Biol. 2003 Mar;141(2-3):141-8. Arch Ital Biol. 2003. PMID: 12825325 Review.
-
Congenital corneal anesthesia.Surv Ophthalmol. 2007 Jan-Feb;52(1):50-60. doi: 10.1016/j.survophthal.2006.10.004. Surv Ophthalmol. 2007. PMID: 17212990 Review.
Cited by
-
The Role of Sensory Innervation in Homeostatic and Injury-Induced Corneal Epithelial Renewal.Int J Mol Sci. 2023 Aug 9;24(16):12615. doi: 10.3390/ijms241612615. Int J Mol Sci. 2023. PMID: 37628793 Free PMC article. Review.
-
Schwann Cells Are Key Regulators of Corneal Epithelial Renewal.Invest Ophthalmol Vis Sci. 2023 Apr 3;64(4):7. doi: 10.1167/iovs.64.4.7. Invest Ophthalmol Vis Sci. 2023. PMID: 37036418 Free PMC article.
-
Nerve growth factor promotes corneal epithelial migration by enhancing expression of matrix metalloprotease-9.Invest Ophthalmol Vis Sci. 2013 Jun 4;54(6):3880-90. doi: 10.1167/iovs.12-10816. Invest Ophthalmol Vis Sci. 2013. PMID: 23640040 Free PMC article.
-
In Vivo Confocal Microscopy of Corneal Nerves in Health and Disease.Ocul Surf. 2017 Jan;15(1):15-47. doi: 10.1016/j.jtos.2016.09.004. Epub 2016 Oct 19. Ocul Surf. 2017. PMID: 27771327 Free PMC article. Review.
-
Neurotrophic Keratopathy in Systemic Diseases: A Case Series on Patients Treated With rh-NGF.Front Med (Lausanne). 2022 May 30;9:920688. doi: 10.3389/fmed.2022.920688. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35707524 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources